Midkine Inhibitor, iMDK-Calbiochem

C₂₁H₁₃FN₂O₂S

376.40

A cell-permeable imidazothiazolyl-chromenone compound that reduces cellular midkine/MDK protein level in H441 lung adenocarcinoma cells in a dose-dependent manner (by >90% in 48 h at 25 nM) via a yet unidentified mechanism. Shown to inhibit the viability of MDK-positive HEK293, H441, and H520 cells (by ≥60% at 500 nM in 48 h), but not MDK-negative NHLF or HEK293 (by <15% at 500 nM in 48 h), via apoptosis induction as a result of PI 3-K/AKT signaling inhibition. Intraperitoneal injection is reported to be efficacious in retarding H441 tumor expansion in mice (9 mg/kg; 3X to 5X per wk) in vivo.
A cell-permeable imidazothiazolyl-chromenone compound that reduces cellular midkine/MDK protein level in H441 lung adenocarcinoma cells in a dose-dependent manner (by >90% in 48 h at 25 nM) via a yet unidentified mechanism, while exhibiting little effect toward cellular level of PTN or VEGF. Shown to inhibit the viability of MDK-positive HEK293, H441, and H520 cells (by ≥60% at 500 nM in 48 h), but not MDK-negative NHLF (normal human lung fibroblast) or HEK293 (by <15% at 500 nM in 48 h), via apoptosis induction as a result of PI 3-K/AKT signaling, but not Erk or p38, pathway inhibition. Intraperitoneal injection is reported to be efficacious in retarding H441 tumor expansion in mice (75% vs 400% increase in tumor volume in 10 d with or without treatment; 3 to 5 times 9 mg/kg i.p. dosing per wk) in vivo.

Cell permeable: yes
Primary Target
Midkine
Reversible: yes

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Hao, H., et al. 2013. PLoS ONE8, e71093.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

100

≥98% (HPLC)

solid

Calbiochem^®

OK to freeze
protect from light

off-white

DMSO: 5 mg/mL

2-8℃

Packaged under inert gas

11 - Combustible Solids

WGK 3